יתרות מזומנים בחישוב למניה Kairos Pharma Limited (KAPA)

Kairos Pharma Ltd (KAPA) minimizes risks by diversifying its tumor resistance programs. The current cash per share on the GURU.Markets base chart is fixed at 0.66. The company develops immunotherapeutic drugs to enhance standard cancer treatments. Specialized medical expertise and the adaptation of management processes ensure sustained investor confidence.
פילוחי מדדים מקיפים ואנליטיקה עבור Kairos Pharma Inc (KAPA)

Portfolio managers evaluate the operating model of Kairos Pharma Ltd (KAPA) through the lens of available capital. This indicator is calculated by dividing total cash reserves by the number of shares, measuring actual liquidity per share. By analyzing the cash per share chart, one can track the rate of R&D resource expenditure in the absence of revenue. This price action reflects the cash burn rate of oncology developments, allowing for the determination of the company's financial sustainability time horizon.